Loading...

Myovant Sciences Ltd ($MYOV)

Stock Image

MYOV Overview

Myovant Sciences, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases.The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd.and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd.operates as a subsidiary of Sumitovant Biopharma Ltd. (From: StockAnalysis.com)

MORE ABOUT Myovant Sciences Ltd

Stay up to date with the best of Bullish each week.

BULLISH WEEKLY

Stay up to date with the best of Bullish each week.

CONVERSATIONS ABOUT Myovant Sciences Ltd